News | February 25, 2009

Clinical Evidence Grows in Support of CyberKnife

February 26, 2009 - Accuray Inc. said its recent 8th Annual CyberKnife Users' Meeting attracted over 500 surgeons, radiation oncologists, medical physicists, hospital administrators and other related clinical staff, many of whom gave presentations on the use of the CyberKnife Robotic Radiosurgery System for the noninvasive treatment of tumors anywhere in the body.

At this year's meeting, nine presentations reported on large-scale studies, each with more than 100 patients with brain, lung or prostate tumors. The 2009 Users' Meeting included 11 presentations related to prostate cancer treatment, with follow-up data approaching three years for many patients. In addition to updated outcomes with longer follow-up, researchers are extending CyberKnife applications for prostate cancer beyond early-stage disease. For example, clinicians discussed their use of CyberKnife radiosurgery to "boost" the radiation dose after conventional radiation therapy for patients with advanced disease, as well as for the treatment of recurrent cancer in patients that failed conventional radiation therapy.

The adoption of CyberKnife radiosurgery for the treatment of lung cancer continues to grow, a trend that was supported by 11 clinical lung cancer presentations. Presenters reported on primary and metastatic lung cancer, the treatment of recurrence after radiation therapy and chemotherapy, and quality of life after lung cancer treatment. In one study, patients showed 94 percent local control of lung tumors at a median follow-up of 33 months.

CyberKnife advantages continue to be extended in brain cancer and other brain disorders, according to the company. Multiple presentations highlighted the CyberKnife System's frameless capability to conveniently treat in multiple sessions — a particularly beneficial capability when lesions are near sensitive critical structures such as those that control vision and hearing. In one study of 114 acoustic neuroma patients, the authors concluded that the CyberKnife System's abilities made radiosurgical treatment possible for more than 13 percent of patients who could not have been treated with single-session radiosurgery because of risk of hearing loss.

For more information: www.accuray.com

Related Content

SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Overall survival of metastatic patients with SABR presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
News | Radiation Oncology | October 30, 2018
October 30, 2018 — In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggre
Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018

Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018.

Feature | Stereotactic Body Radiation Therapy (SBRT) | October 23, 2018 | By Greg Freiherr
With its shorter course of treatment,...
CyberKnife System Provides Excellent Prostate Cancer Survival Rates in Five or Fewer Sessions
News | Stereotactic Body Radiation Therapy (SBRT) | September 27, 2018
Accuray Inc. announced that published data from two prospective, multi-center studies using differing protocols provide...
First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System
News | Stereotactic Body Radiation Therapy (SBRT) | April 06, 2018
Accuray Inc. and Erasmus MC announced the first patient has been successfully treated using an online-adaptive (OA)...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Age Impacts Post-treatment Mortality for Early-stage Lung Cancer Patients

Image courtesy of Henri Becquerel Cancer Center

News | Stereotactic Body Radiation Therapy (SBRT) | January 24, 2018
A University of Colorado Cancer Center study published in the Journal of Clinical Oncology explores mortality in the...
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...